109 related articles for article (PubMed ID: 34554986)
1. More Adverse Events with Home Infusions.
Rosenberg K
Am J Nurs; 2021 Oct; 121(10):51. PubMed ID: 34554986
[TBL] [Abstract][Full Text] [Related]
2. Home vs Hospital Infusion of Biologic Agents for Patients With Inflammatory Bowel Diseases.
Fenster M; Ungaro RC; Hirten R; Gallinger Z; Cohen L; Atreja A; Mehandru S; Colombel JF; Cohen BL
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):257-258. PubMed ID: 30910602
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Adverse Events Among Home- vs Facility-Administered Biologic Infusions, 2007-2017.
Baker MC; Weng Y; Fairchild R; Ahuja N; Rohatgi N
JAMA Netw Open; 2021 Jun; 4(6):e2110268. PubMed ID: 34081140
[TBL] [Abstract][Full Text] [Related]
4. Short article: Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease.
Kuin S; Stolte SB; van den Brink GR; Ponsioen CY; Fockens P; D'Haens GR; Löwenberg M
Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):222-5. PubMed ID: 26566062
[TBL] [Abstract][Full Text] [Related]
5. Thrombophlebitis of cephalic vein in the left forearm related to infliximab infusion.
Huang ZY; Lin L; Tang Q; Wang YF
J Dig Dis; 2016 Nov; 17(11):773-776. PubMed ID: 27598885
[No Abstract] [Full Text] [Related]
6. Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases.
Giese-Kim N; Wu M; Dehghan M; Sceats LA; Park KT
Am J Gastroenterol; 2020 Oct; 115(10):1698-1706. PubMed ID: 32701731
[TBL] [Abstract][Full Text] [Related]
7. Swift Efficacy with Infliximab 4 Years after Initial Standard Induction Therapy Followed by Severe Delayed Infusion Reaction in Crohn's Disease.
Chiba M; Tsuji T; Nakane K; Obara Y; Komatsu M
Inflamm Bowel Dis; 2020 Jan; 26(1):e4. PubMed ID: 31697829
[No Abstract] [Full Text] [Related]
8. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability.
Bohra A; Rizvi QA; Keung CYY; Vasudevan A; van Langenberg DR
World J Gastroenterol; 2020 Sep; 26(36):5437-5449. PubMed ID: 33024395
[TBL] [Abstract][Full Text] [Related]
9. Rapid Infliximab Infusion in Children: A Multicenter Retrospective Cohort Study.
Lev-Tzion R; Assa A; Yerushalmi B; Lahad A; Friedman M; Ledder O; Turner D
J Pediatr Gastroenterol Nutr; 2017 Nov; 65(5):e101-e103. PubMed ID: 29064928
[TBL] [Abstract][Full Text] [Related]
10. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?
Bhat S; Sharma D; Doherty P; Tham TC; Caddy GR
Inflamm Bowel Dis; 2010 Nov; 16(11):1922-5. PubMed ID: 20848465
[TBL] [Abstract][Full Text] [Related]
11. Frequency of Severe Infusion Reactions Associated With Outpatient Infusion of Infliximab Without Premedications.
Hutsell SQ; Wu M; Park KT
J Pediatr Gastroenterol Nutr; 2017 Oct; 65(4):430-431. PubMed ID: 28937551
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
Yang E; Panaccione N; Whitmire N; Dulai PS; Vande Casteele N; Singh S; Boland BS; Collins A; Sandborn WJ; Panaccione R; Battat R
Aliment Pharmacol Ther; 2020 Jun; 51(11):1031-1038. PubMed ID: 32329532
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Rapid vs Standard Infliximab Infusions in the Pediatric Population.
Rozette NA; Hellauer CM; McKee C; Vazifedan T; Gabriel CA; Dice JE; Yokois NU
Inflamm Bowel Dis; 2018 Aug; 24(9):2007-2014. PubMed ID: 29788416
[TBL] [Abstract][Full Text] [Related]
14. Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting.
Checkley LA; Kristofek L; Kile S; Bolgar W
Dig Dis Sci; 2019 Mar; 64(3):855-862. PubMed ID: 30311152
[TBL] [Abstract][Full Text] [Related]
15. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.
Ben-Horin S; Ungar B; Kopylov U; Lahat A; Yavzori M; Fudim E; Picard O; Peled Y; Eliakim R; Del Tedesco E; Paul S; Roblin X
Aliment Pharmacol Ther; 2018 Apr; 47(8):1117-1125. PubMed ID: 29446098
[TBL] [Abstract][Full Text] [Related]
16. Adherence to intravenous biological treatment in inflammatory bowel disease patients during the COVID-19 pandemic.
Suárez Ferrer C; Pérez Robles T; Martín-Arranz MD
Rev Esp Enferm Dig; 2021 Feb; 113(2):154. PubMed ID: 33371704
[TBL] [Abstract][Full Text] [Related]
17. A home infliximab infusion program.
Condino AA; Fidanza S; Hoffenberg EJ
J Pediatr Gastroenterol Nutr; 2005 Jan; 40(1):67-9. PubMed ID: 15625429
[TBL] [Abstract][Full Text] [Related]
18. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study.
Van Assche G; Vermeire S; Noman M; Amant C; Weyts E; Vleminckx A; Vermeyen MJ; Rutgeerts P
J Crohns Colitis; 2010 Sep; 4(3):329-33. PubMed ID: 21122522
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing acute infusion reactions in inflammatory bowel disease patients treated with infliximab in the era of scheduled maintenance therapy.
Duron C; Goutte M; Pereira B; Bommelaer G; Buisson A
Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):705-11. PubMed ID: 25856689
[TBL] [Abstract][Full Text] [Related]
20. New-Onset Diffuse Parenchymal Lung Disease in a 52-Year-Old Woman With Ulcerative Colitis.
De Backer E; Bode H; Baert F
Gastroenterology; 2020 Feb; 158(3):478-479. PubMed ID: 31560891
[No Abstract] [Full Text] [Related]
[Next] [New Search]
